Oxidative Stress and Asprosin Levels in Type 2 Diabetic Patients with Good and Poor Glycemic Control

HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship...

Full description

Saved in:
Bibliographic Details
Published inBiomolecules (Basel, Switzerland) Vol. 14; no. 9; p. 1123
Main Authors Senyigit, Abdulhalim, Durmus, Sinem, Gelisgen, Remise, Uzun, Hafize
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 05.09.2024
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
Abstract HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient's glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications.
AbstractList Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. Materials and Methods: The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient's glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. Results: The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Conclusions: Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications.Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. Materials and Methods: The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient's glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. Results: The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Conclusions: Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications.
Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. Materials and Methods: The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient’s glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. Results: The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Conclusions: Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications.
HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient's glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications.
Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels can be reduced with good glycemic control (GC) and thus prevented or delayed micro/macro complications in patients with T2DM. The relationship between asprosin, which is thought to affect GC, and oxidative stress parameters such as lipid hydroperoxides (LOOHs), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (Cu,Zn-SOD), and total antioxidant capacity (TAC) was evaluated in T2DM patients. Materials and Methods: The study was conducted prospectively in 75 healthy people admitted to the hospital for a general health check-up and 150 T2DM patients treated in the diabetes outpatient clinic. The patient’s glycemic status measurements were categorized as good glycemic control group (GGC) is defined as HbA1c < 7 and poor glycemic control (PGC) group is defined as HbA1c ≥ 7. Results: The study found a consistent increase in LOOH and MDA levels across the control, GGC, and PGC groups, while GSH, Cu/Zn-SOD, and TAC levels decreased in these respective groups. Additionally, asprosin levels showed a gradual rise in all groups. Positive correlations were observed between asprosin levels and various metabolic and oxidative stress markers, including BMI, WC, FBG, insulin, homeostasis model assessment for insulin resistance (HOMA-IR), DM duration, LOOH, and MDA, while negative correlations were noted with GSH, Cu/Zn-SOD, and TAC specifically in the PGC group. Furthermore, multivariate regression analysis identified HOMA-IR as the primary influencing factor on asprosin levels in PGC patients. Conclusions: Current glycemic dysregulation may lead to increased circulating asprosin and oxidative stress, which cause complications. Since asprosin levels may be an important hormonal factor in determining GC in T2DM, the use of this hormone may be recommended in the future to accelerate therapeutic approaches in T2DM. Early diagnosis and appropriate treatment may delay the development and progression of diabetic complications.
Audience Academic
Author Uzun, Hafize
Senyigit, Abdulhalim
Durmus, Sinem
Gelisgen, Remise
AuthorAffiliation 2 Department of Medical Biochemistry, Faculty of Medicine, Izmir Katip Celebi University, Izmir 35620, Türkiye; durmus.sinem@gmail.com
3 Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34320,Türkiye; remise.gelisgen@iuc.edu.tr
1 Department of Internal Medicine, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye; abdulhalim.senyigit@atlas.edu.tr
4 Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye
AuthorAffiliation_xml – name: 3 Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34320,Türkiye; remise.gelisgen@iuc.edu.tr
– name: 1 Department of Internal Medicine, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye; abdulhalim.senyigit@atlas.edu.tr
– name: 4 Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye
– name: 2 Department of Medical Biochemistry, Faculty of Medicine, Izmir Katip Celebi University, Izmir 35620, Türkiye; durmus.sinem@gmail.com
Author_xml – sequence: 1
  givenname: Abdulhalim
  surname: Senyigit
  fullname: Senyigit, Abdulhalim
  organization: Department of Internal Medicine, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye
– sequence: 2
  givenname: Sinem
  orcidid: 0000-0002-9272-9098
  surname: Durmus
  fullname: Durmus, Sinem
  organization: Department of Medical Biochemistry, Faculty of Medicine, Izmir Katip Celebi University, Izmir 35620, Türkiye
– sequence: 3
  givenname: Remise
  surname: Gelisgen
  fullname: Gelisgen, Remise
  organization: Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul 34320,Türkiye
– sequence: 4
  givenname: Hafize
  orcidid: 0000-0002-1347-8498
  surname: Uzun
  fullname: Uzun, Hafize
  organization: Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Türkiye
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39334889$$D View this record in MEDLINE/PubMed
BookMark eNptkk1vEzEQhleoiJbSG2dkiUsPpPgzuz6hKNBQKVIrUSRulteeTR1t1sHeBPLvO0lKSRC2JVvjdx7PeOZ1cdLFDoriLaNXQmj6sQ5xwSTVjHHxojjjnFUDXoofJwfn0-Ii5znFUeHi4lVxKrQQsqr0WeFvfwdv-7AG8q1PkDOxnSejvEwxh45MYQ1tJni63yyBcPI52Br64MgdOkHXZ_Ir9A9kEqPfed7FmMik3ThYoGgcuz7F9k3xsrFthoun_bz4fv3lfvx1ML2d3IxH04GTQvSDuhSSQ2WVa1ytatCeSy4bVlElLNXVUFutJBXWOeps08ihKxWTlnlJh8C9OC9u9lwf7dwsU1jYtDHRBrMzxDQzNmHwLZiaUXAIU8qVkvtS60px8NIOlWOiVsj6tGctV_UCvMNck22PoMc3XXgws7g2jElBhxVFwuUTIcWfK8i9WYTsoG1tB3GVjWCMaqwJ1yh9_490Hlepw7_aqUTJMci_qpnFDELXRHzYbaFmVCFLaVlun736jwqn35YE26cJaD9y-LB3cFjznKB5TpJRs-0yc9hlKH93-DHP4j89JR4BQfTMtg
Cites_doi 10.1080/09513590.2018.1512967
10.1152/physrev.00018.2001
10.1016/S0076-6879(78)52032-6
10.2337/dc20-S002
10.3390/ijms14023265
10.2174/1573399816666200716201550
10.1080/0886022X.2023.2220425
10.1093/clinchem/34.3.497
10.1007/s11033-021-06551-2
10.2337/dc09-S310
10.1016/0003-2697(92)90122-N
10.1155/2018/9471583
10.1186/s13104-019-4248-6
10.1007/BF02913083
10.1155/2021/6622129
10.3390/cimb45080420
10.1155/2018/7375294
10.2337/dc18-Sint01
10.4137/BMI.S38440
10.1186/1475-2840-4-5
10.1006/abio.1996.0292
10.4158/EP15672.GLSUPPL
10.1016/j.biocel.2006.07.001
10.1186/s13098-020-00564-w
10.1111/dom.13891
10.3389/fendo.2020.00064
10.1016/j.cca.2017.10.034
10.2337/dc18-S002
10.1038/nm.4432
10.12816/0003082
10.1159/000503808
10.1016/j.cell.2016.02.063
10.1111/jocn.14779
10.1007/s10517-021-05191-7
10.7554/eLife.63784
ContentType Journal Article
Copyright COPYRIGHT 2024 MDPI AG
2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2024 by the authors. 2024
Copyright_xml – notice: COPYRIGHT 2024 MDPI AG
– notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2024 by the authors. 2024
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7T5
7TM
7TO
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.3390/biom14091123
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database
MEDLINE
CrossRef



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2218-273X
ExternalDocumentID oai_doaj_org_article_b10ec54055c742d799852ed4a65c13b5
A810959470
10_3390_biom14091123
39334889
Genre Journal Article
GeographicLocations Istanbul Turkey
Turkey
United States--US
Germany
GeographicLocations_xml – name: Germany
– name: United States--US
– name: Istanbul Turkey
– name: Turkey
GroupedDBID 3V.
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
AADQD
AAFWJ
ABDBF
ABUWG
ADBBV
AFKRA
AFPKN
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
EBD
ECM
EIF
ESX
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
IAO
ITC
KQ8
LK8
M1P
M7P
MODMG
M~E
NPM
OK1
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RIG
RPM
UKHRP
AAYXX
CITATION
7T5
7TM
7TO
7XB
8FK
AZQEC
DWQXO
GNUQQ
H94
K9.
M48
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c433t-b7342e8a5cfcb5be9d2424f18053a09869a95403acc0caff46c7514a1d406e2d3
IEDL.DBID RPM
ISSN 2218-273X
IngestDate Tue Oct 22 15:09:52 EDT 2024
Mon Sep 30 11:48:15 EDT 2024
Sat Oct 26 02:12:15 EDT 2024
Thu Oct 10 21:11:05 EDT 2024
Thu Oct 10 02:26:40 EDT 2024
Tue Oct 08 04:17:17 EDT 2024
Wed Sep 11 14:10:30 EDT 2024
Sat Nov 02 12:02:25 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords T2DM
glycemic control
asprosin
total antioxidant capacity
glutathione
superoxide dismutase
malondialdehyde
lipid hydroperoxides
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c433t-b7342e8a5cfcb5be9d2424f18053a09869a95403acc0caff46c7514a1d406e2d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9272-9098
0000-0002-1347-8498
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11430680/
PMID 39334889
PQID 3110372742
PQPubID 2032425
ParticipantIDs doaj_primary_oai_doaj_org_article_b10ec54055c742d799852ed4a65c13b5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11430680
proquest_miscellaneous_3110908029
proquest_journals_3110372742
gale_infotracmisc_A810959470
gale_infotracacademiconefile_A810959470
crossref_primary_10_3390_biom14091123
pubmed_primary_39334889
PublicationCentury 2000
PublicationDate 20240905
PublicationDateYYYYMMDD 2024-09-05
PublicationDate_xml – month: 9
  year: 2024
  text: 20240905
  day: 5
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Biomolecules (Basel, Switzerland)
PublicationTitleAlternate Biomolecules
PublicationYear 2024
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Li (ref_37) 2018; 2018
Romere (ref_9) 2016; 165
Sherwani (ref_2) 2016; 11
Monnier (ref_4) 2009; 32
Goodarzi (ref_24) 2021; 48
Duerrschmid (ref_8) 2017; 23
Handelsman (ref_5) 2015; 21
Johansen (ref_12) 2005; 4
Mishra (ref_39) 2021; 10
Beutler (ref_18) 1963; 61
Jiang (ref_16) 1992; 202
Wang (ref_22) 2019; 75
ref_19
Sun (ref_20) 1988; 34
Caturano (ref_35) 2023; 45
Benzie (ref_21) 1996; 239
ref_15
Zhou (ref_26) 2023; 45
Zhang (ref_28) 2019; 489
Wang (ref_25) 2018; 2018
Verma (ref_31) 2006; 21
(ref_10) 2002; 82
Matough (ref_13) 2012; 12
Naiemian (ref_23) 2020; 12
Ghouse (ref_32) 2020; 22
(ref_3) 2010; 135
Milo (ref_30) 2019; 28
Ugur (ref_27) 2022; 26
ref_1
Buege (ref_17) 1978; 52
Alan (ref_36) 2019; 35
Rabelo (ref_14) 2013; 14
Valente (ref_33) 2021; 17
Darenskaya (ref_34) 2021; 171
Valko (ref_11) 2007; 39
ref_29
Hong (ref_38) 2021; 2021
ref_7
ref_6
References_xml – volume: 35
  start-page: 220
  year: 2019
  ident: ref_36
  article-title: Asprosin: A novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome
  publication-title: Gynecol. Endocrinol.
  doi: 10.1080/09513590.2018.1512967
  contributor:
    fullname: Alan
– volume: 82
  start-page: 47
  year: 2002
  ident: ref_10
  article-title: Free radicals in the physiological control of cell function
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.00018.2001
– volume: 52
  start-page: 302
  year: 1978
  ident: ref_17
  article-title: Microsomal lipid peroxidation
  publication-title: Methods Enzymol.
  doi: 10.1016/S0076-6879(78)52032-6
  contributor:
    fullname: Buege
– ident: ref_1
  doi: 10.2337/dc20-S002
– volume: 14
  start-page: 3265
  year: 2013
  ident: ref_14
  article-title: Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms14023265
  contributor:
    fullname: Rabelo
– volume: 135
  start-page: 15
  year: 2010
  ident: ref_3
  article-title: Assessment of glycemic control: New insights into the evaluation of the diabetic patient
  publication-title: Med. Clin.
– volume: 17
  start-page: e071620183816
  year: 2021
  ident: ref_33
  article-title: Glycemic Variability, Oxidative Stress, and Impact on Complications Related to Type 2 Diabetes Mellitus
  publication-title: Curr. Diabetes Rev.
  doi: 10.2174/1573399816666200716201550
  contributor:
    fullname: Valente
– volume: 45
  start-page: 2220425
  year: 2023
  ident: ref_26
  article-title: Asprosin is positively associated with metabolic syndrome in hemodialysis patients: A cross-sectional study
  publication-title: Ren. Fail.
  doi: 10.1080/0886022X.2023.2220425
  contributor:
    fullname: Zhou
– volume: 34
  start-page: 497
  year: 1988
  ident: ref_20
  article-title: A simple method for clinical assay of superoxide dismutase
  publication-title: Clin. Chem.
  doi: 10.1093/clinchem/34.3.497
  contributor:
    fullname: Sun
– volume: 48
  start-page: 5443
  year: 2021
  ident: ref_24
  article-title: Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy
  publication-title: Mol. Biol. Rep.
  doi: 10.1007/s11033-021-06551-2
  contributor:
    fullname: Goodarzi
– volume: 32
  start-page: S199
  year: 2009
  ident: ref_4
  article-title: Target for glycemic control: Concentrating on glucose
  publication-title: Diabetes Care
  doi: 10.2337/dc09-S310
  contributor:
    fullname: Monnier
– volume: 202
  start-page: 384
  year: 1992
  ident: ref_16
  article-title: Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein
  publication-title: Anal. Biochem.
  doi: 10.1016/0003-2697(92)90122-N
  contributor:
    fullname: Jiang
– volume: 2018
  start-page: 9471583
  year: 2018
  ident: ref_25
  article-title: Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion
  publication-title: Mediat. Inflamm.
  doi: 10.1155/2018/9471583
  contributor:
    fullname: Wang
– ident: ref_29
  doi: 10.1186/s13104-019-4248-6
– volume: 21
  start-page: 142
  year: 2006
  ident: ref_31
  article-title: Effect of increasing duration of diabetes mellitus type 2 on glycated hemoglobin and insulin sensitivity
  publication-title: Indian. J. Clin. Biochem.
  doi: 10.1007/BF02913083
  contributor:
    fullname: Verma
– volume: 2021
  start-page: 6622129
  year: 2021
  ident: ref_38
  article-title: High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome
  publication-title: Int. J. Endocrinol.
  doi: 10.1155/2021/6622129
  contributor:
    fullname: Hong
– volume: 61
  start-page: 882
  year: 1963
  ident: ref_18
  article-title: Improved method for the determination of blood glutathione
  publication-title: J. Lab. Clin. Med.
  contributor:
    fullname: Beutler
– volume: 45
  start-page: 6651
  year: 2023
  ident: ref_35
  article-title: Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications
  publication-title: Curr. Issues Mol. Biol.
  doi: 10.3390/cimb45080420
  contributor:
    fullname: Caturano
– volume: 2018
  start-page: 7375294
  year: 2018
  ident: ref_37
  article-title: Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases
  publication-title: Mediat. Inflamm.
  doi: 10.1155/2018/7375294
  contributor:
    fullname: Li
– ident: ref_6
  doi: 10.2337/dc18-Sint01
– volume: 11
  start-page: 95
  year: 2016
  ident: ref_2
  article-title: Signifcance of HbA1c test in diagnosis and prognosis of diabetic patients
  publication-title: Biomark. Insights
  doi: 10.4137/BMI.S38440
  contributor:
    fullname: Sherwani
– volume: 4
  start-page: 5
  year: 2005
  ident: ref_12
  article-title: Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice
  publication-title: Cardiovasc. Diabetol.
  doi: 10.1186/1475-2840-4-5
  contributor:
    fullname: Johansen
– volume: 239
  start-page: 70
  year: 1996
  ident: ref_21
  article-title: The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay
  publication-title: Anal. Biochem.
  doi: 10.1006/abio.1996.0292
  contributor:
    fullname: Benzie
– volume: 21
  start-page: 1
  year: 2015
  ident: ref_5
  article-title: American association of clinical endocrinologists and American college of endocrinology—Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015
  publication-title: Endocr. Pract.
  doi: 10.4158/EP15672.GLSUPPL
  contributor:
    fullname: Handelsman
– volume: 39
  start-page: 44
  year: 2007
  ident: ref_11
  article-title: Free radicals and antioxidants in normal physiological functions and human disease
  publication-title: Int. J. Biochem. Cell Biol.
  doi: 10.1016/j.biocel.2006.07.001
  contributor:
    fullname: Valko
– volume: 12
  start-page: 65
  year: 2020
  ident: ref_23
  article-title: Serum concentration of asprosin in new-onset type 2 diabetes
  publication-title: Diabetol. Metab. Syndr.
  doi: 10.1186/s13098-020-00564-w
  contributor:
    fullname: Naiemian
– volume: 26
  start-page: 2124
  year: 2022
  ident: ref_27
  article-title: Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
  contributor:
    fullname: Ugur
– volume: 22
  start-page: 231
  year: 2020
  ident: ref_32
  article-title: Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes
  publication-title: Diabetes Obes. Metab.
  doi: 10.1111/dom.13891
  contributor:
    fullname: Ghouse
– ident: ref_7
  doi: 10.3389/fendo.2020.00064
– volume: 489
  start-page: 183
  year: 2019
  ident: ref_28
  article-title: Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride
  publication-title: Clin. Chim. Acta
  doi: 10.1016/j.cca.2017.10.034
  contributor:
    fullname: Zhang
– ident: ref_15
  doi: 10.2337/dc18-S002
– volume: 23
  start-page: 1444
  year: 2017
  ident: ref_8
  article-title: Asprosin is a centrally acting orexigenic hormone
  publication-title: Nat. Med.
  doi: 10.1038/nm.4432
  contributor:
    fullname: Duerrschmid
– ident: ref_19
– volume: 12
  start-page: 5
  year: 2012
  ident: ref_13
  article-title: The role of oxidative stress and antioxidants in diabetic complications
  publication-title: Sultan Qaboos Univ. Med. J.
  doi: 10.12816/0003082
  contributor:
    fullname: Matough
– volume: 75
  start-page: 205
  year: 2019
  ident: ref_22
  article-title: Serum Asprosin Concentrations Are Increased and Associated with Insulin Resistance in Children with Obesity
  publication-title: Ann. Nutr. Metab.
  doi: 10.1159/000503808
  contributor:
    fullname: Wang
– volume: 165
  start-page: 566
  year: 2016
  ident: ref_9
  article-title: Asprosin, a Fasting-Induced Glucogenic Protein Hormone
  publication-title: Cell
  doi: 10.1016/j.cell.2016.02.063
  contributor:
    fullname: Romere
– volume: 28
  start-page: 1737
  year: 2019
  ident: ref_30
  article-title: Predictors of glycemic management among patients with type 2 diabetes
  publication-title: J. Clin. Nurs.
  doi: 10.1111/jocn.14779
  contributor:
    fullname: Milo
– volume: 171
  start-page: 179
  year: 2021
  ident: ref_34
  article-title: Oxidative Stress: Pathogenetic Role in Diabetes Mellitus and Its Complications and Therapeutic Approaches to Correction
  publication-title: Bull. Exp. Biol. Med.
  doi: 10.1007/s10517-021-05191-7
  contributor:
    fullname: Darenskaya
– volume: 10
  start-page: e63784
  year: 2021
  ident: ref_39
  article-title: Asprosin-neutralizing antibodies as a treatment for metabolic syndrome
  publication-title: eLife
  doi: 10.7554/eLife.63784
  contributor:
    fullname: Mishra
SSID ssj0000800823
Score 2.3474157
Snippet HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative stress levels...
Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative...
Objectives: HbA1c is the most widely used test as an indicator of glucoregulation in patients with type 2 diabetes mellitus (T2DM). Asprosin and oxidative...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1123
SubjectTerms Adipokines
Adult
Aged
Antilipemic agents
Antioxidants
Antioxidants - metabolism
asprosin
Biomarkers - blood
Blood diseases
Blood Glucose - metabolism
Blood sugar
Body mass index
Creatinine
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - metabolism
Diabetes therapy
Diabetics
Female
Fibrillin-1 - blood
Fibrillin-1 - metabolism
Free radicals
Glucose
Glutathione
Glutathione - blood
Glutathione - metabolism
Glycated Hemoglobin - analysis
Glycated Hemoglobin - metabolism
Glycemic Control
Hemoglobin
Homeostasis
Hospitals
Humans
Insulin
Insulin resistance
Laboratories
lipid hydroperoxides
Lipid peroxidation
Lipids
Male
malondialdehyde
Malondialdehyde - blood
Malondialdehyde - metabolism
Medical research
Medicine, Experimental
Middle Aged
Outpatient care facilities
Oxidative Stress
Patients
Prospective Studies
Proteins
Superoxide dismutase
Superoxide Dismutase - blood
Superoxide Dismutase - metabolism
T2DM
Urine
Zinc
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQUB6BgozE4xTVsZONfVwq2grxqASVerPssSMWQYKarUT_PTN2ukrEgQu3KHYSZx7xjPPNZ8ZeCu2IGEuUQPyXtWvr0hsvyqarguhk8CHtdfjx0-r0vH5_0VzMtvoiTFimB86CO_SViEBhRYN3k6HF9KCRMdRu1UClfGYvFWaWTH2f4iAtVUa6K8zrD6mancidML5QizkoUfX__UGezUhLtORs-jm-y-5McSNf5_HeY7dif5_tr3vMmX9e89c8ITnTEvk-C59_b0Ii9OZfUikId33g6xEfOm56_oFwQiPHI0pCueQZFbMBfpZJVkdOq7P8ZBhCuvJsGC75yY9rICA9P8rg9gfs_Pjd16PTctpNoYRaqW3pW1XLqF0DHfjGRxOoMqSrNLqhE0avjDMoZ-UABLiuq1fQYjTlqoBzfpRBPWR7_dDHx4xLTzepMPbDbiEYB06DEx0Ge8FDFAV7dSNf-yuTZlhMNkgPdq6Hgr0l4e_6ENV1OoEGYCcDsP8ygIK9IdVZckjUD7iprgCHStRWdq0rWuusWxzWwaInOhIsm2-UbydHHq2qqJCS_mcX7MWuma4kcFofh6vcx1DNsinYo2wru1dShkqdNbbohRUt3nnZ0m--JZpvzFQV7Yzy5H9I6Sm7LTEcS-i45oDtbS-v4jMMp7b-efKcPybeHSc
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLage-EFDcYlYyAjcXmK5thJYz-hbtpFCEYFTNqb5VugEiSj6ST27znHcUsjJN6q2mmdHB_7Oyff-UzIKyYNCmOx3KH-ZWnqMrfKsrxqCs8a7q2PZx1-vJieX5bvr6qrlHDrE61yvSbGhdp3DnPkh6LAijZ8sfju-leOp0bh29V0hMZdssMhUmATsnN0cjH_vMmyIB6SXAyMdwHx_SFWtaPIE-AMMdqLomT_vwvz1s40Zk1ubUOnu-R-wo90Nhj8AbkT2odkb9ZC7Pzzlr6hkdEZU-V7xH_6vfBR2Jt-iSUh1LSeznr4037R0g_IF-opfMJglHI6sGMWjs4HsdWeYpaWnnWdj1fOu25Jz37cOiTU0-OB5P6IXJ6efD0-z9OpCrkrhVjlthYlD9JUrnG2skF5rBBpCgnuaJiSU2UUwDhhnGPONE05dTWgKlN42PsD9-IxmbRdG54Syi3-SAEYELp5r4wz0hnWAOjz1gWWkdfr56uvB_EMDUEH2kFv2yEjR_jwN31Q8jp-0S2_6eRB2hYsOMSXFUwr7muIEysefGmmlSuErTLyFk2n0THBPs6k-gIYKkpc6ZksMOdZ1jCsg1FPcCg3bl4bXyeH7vXf6ZeRl5tmvBJJam3oboY-CmuXVUaeDHNlc0tCYcmzhBY5mkWjex63tIvvUe4bIlaBJ6Ts_39cz8g9DoAr8t-qAzJZLW_CcwBMK_siecUfdxgWkQ
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwEB4ty4ULApZHYEFG4nEKJE7c2AeEyordFeKxElTqzfIrULQk0HSl7b9nxkmrRou4VbWTOp5x_Y3zzTcAzzJpSBgrSx3pX5amKlOrbJaKOvdZzb31sdbhp8-T01n5YS7me7CpNjpMYPfP0I7qSc2W568u_6zf4oJ_QxEnhuyvKVGddJsQOhTX4DovMUYnEt8A9H8OuEjGWm8c9zTKR5n3LPgrNxjtT1HG_-qf9c5uNWZS7mxNx7fg5oAp2bR3gtuwF5o7cDBtMJ7-tWYvWGR5xuPzA_BfLhc-in2zrzFNhJnGs2mHP9otGvaROEQdw08UoDLOesbMwrGzXoC1Y3Ryy07a1scrz9p2yU7O145I9uyoJ77fhdnx-29Hp-lQaSF1OFmr1FZFyYM0wtXOChuUp6yROpe4RE2m5EQZhdCuMM5lztR1OXEVIi2Te8QDgfviHuw3bRMeAOOWbpIjLsRu3ivjjHQmqxEIeutClsDzzfzq372ghsZAhOygd-2QwDua_G0fksGOX7TL73pYVdrmWXCEOQW6GvcVxo6CB1-aiXB5YUUCL8l0mtwH7ePMkHOAQyXZKz2VOZ2DlhUO63DUExeZGzdvjK83PqqLnJIs6V13Ak-3zXQlEdea0F70fRTlM6sE7ve-sn2kQlEatMQWOfKi0TOPW5rFjygBjlFsQVVTHv5_2I_gBkcQFjlx4hD2V8uL8BhB1Mo-ievjL_7VGZ8
  priority: 102
  providerName: Scholars Portal
Title Oxidative Stress and Asprosin Levels in Type 2 Diabetic Patients with Good and Poor Glycemic Control
URI https://www.ncbi.nlm.nih.gov/pubmed/39334889
https://www.proquest.com/docview/3110372742
https://www.proquest.com/docview/3110908029
https://pubmed.ncbi.nlm.nih.gov/PMC11430680
https://doaj.org/article/b10ec54055c742d799852ed4a65c13b5
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB615cIFAeVhWqJF4nFyY3v9PKZRH0KkRECl3Kx9uRg1dhWnUvvvmVnbkS1uXKIouxuvPTPZbzbffAvw0UsFCWN5riL9y1AkoSsz6blR4WuvCLTU9qzDxVV8eR1-XUWrPYj7WhhL2leyPKlu1ydV-dtyK-_WatrzxKbLxRwxPKczI6b7sI8eOsjR_3QYKA14y3LnmNNPqZKdhJ0QW9C5OTyj8lM62H2wFFnF_n9_lwcL05g0OViFzp_Dsw4-slk7zRewZ6qXcDirMHVeP7LPzBI67U75IejvD6W2ut7sp60IYaLSbNbgRZuyYt-ILtQwfEe5KAtYS44pFVu2WqsNo01adlHX2o5c1vWGXdw-KuLTs3nLcX8F1-dnv-aXbneogqtCzreuTHgYmFREqlAykibTVCBS-ClGo_CyNM5EhiiOC6U8JYoijFWCoEr4Gpd-E2j-Gg6qujJvgQWSvsRHCIjdtM6EEqkSXoGYT0tlPAc-9c83v2u1M3LMOcgk-dAkDpzSw9_1IcVr-0G9uck7u-fS94wieBmhVwU6wTQxCowORRwpn8vIgS9kupziEu2jRFdegFMlhat8lvq05RkmOK3jUU-MJzVu7o2fd_Hc5Nynekr6W9uBD7tmGkkctcrU922fjEqXMwfetL6yu6Xe5RxIR140uudxCzq_Vfvunf3d_w89gqcBYjFLjYuO4WC7uTfvEUtt5QQDaJVM4Mnp2dXyx8TuSODrIkwnNqj-AhWgIvE
link.rule.ids 230,315,730,783,787,867,888,2109,2228,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806,74079,74636
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgPMALAgYsbICR-HiK5sRxYz-hMrEV6MYkNqlvlr-yVYJkazqJ_ffcOWlphMRbFTup4_PZd5ff_Y6Qt0waJMZiqUP-y8KURWqVZamoMs-q3Fsfax0en4wm58XXmZj1Abe2h1Wu9sS4UfvGYYx8n2eY0YYfFj9eXadYNQq_rvYlNO6Se8jDhRUMylm5jrGgNSRz3uHdOXj3-5jTjhRPYGXwwUkUCfv_3ZY3zqUhZnLjEDp8RB721iMdd-J-TO6E-gnZHtfgOf-6pe9pxHPGQPk28d9_z32k9aY_YkIINbWn4xb-tJ3XdIpooZbCL3RFaU47bMzc0dOOarWlGKOlR03j452nTbOgRz9vHcLp6UEHcX9Kzg8_nx1M0r6mQupghpapLXmRB2mEq5wVNiiP-SFVJkEZDVNypIwCI44b55gzVVWMXAk2lck8nPwh9_wZ2aqbOuwQmlt8SAYWIHTzXhlnpDOsApPPWxdYQt6t5ldfddQZGlwOlIPelENCPuHkr_sg4XW80CwudK8_2mYsOLQuBSyq3JfgJYo8-MKMhMu4FQn5gKLTqJYgH2f67AIYKhJc6bHMMOJZlDCsvUFPUCc3bF4JX_fq3Oq_iy8hb9bNeCdC1OrQ3HR9FGYuq4Q879bK-pW4woRnCS1ysIoG7zxsqeeXkewb_FWO9VFe_H9cr8n9ydnxVE-_nHzbJQ9yML0iEk7ska3l4ia8BNNpaV9F_fgDDuAYHA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSIiXCRgfgTGMxMdT1MROGvsJdYNuwBiVYFLfLH-FVYJkNJ3E_nvuHLc0QuKtqp3Wyd3Zv7v87o6Ql5nQWBgrSy3Wvyx0VaRGmiwt69xlNXPGhV6Hn8_GJ-fFx3k5j_ynLtIq13ti2KhdazFGPuI5ZrThi8VRHWkRs3fTt5e_UuwghW9aYzuNm-RWBV4Kang1rzbxFkRGgvGe-87B0x9hfjuWewLEwQenUije_-8WvXVGDfmTWwfS9C7ZjUiSTnrR3yM3fHOf7E0a8KJ_XtPXNHA7Q9B8j7gvvxculPimX0NyCNWNo5MO_rRbNPQUmUMdhU_ollJGe57MwtJZX3a1oxivpcdt68KVs7Zd0uMf1xap9fSop7s_IOfT99-OTtLYXyG1Beer1FS8YF7o0tbWlMZLh7kidS7AMHUmxVhqCYCOa2szq-u6GNsK8JXOHaAAzxx_SHaatvGPCWUGfyQHNAjTnJPaamF1VgP8c8b6LCGv1s9XXfZlNBS4HygHtS2HhBziw9_MweLX4Yt2-V1FW1Imz7xFpFmCgjFXgcdYMu8KPS5tzk2ZkDcoOoUmCvKxOmYawFKx2JWaiByjn0UFy9ofzATTssPhtfBVNO1O_VXEhLzYDOOVSFdrfHvVz5GYxSwT8qjXlc0tcYnJzwJGxECLBvc8HGkWF6HwN_iuHHulPPn_up6T22Aa6vTD2aen5A4DFBZIceU-2Vktr_wzQFErcxDM4w9KQRxa
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oxidative+Stress+and+Asprosin+Levels+in+Type+2+Diabetic+Patients+with+Good+and+Poor+Glycemic+Control&rft.jtitle=Biomolecules+%28Basel%2C+Switzerland%29&rft.au=Senyigit%2C+Abdulhalim&rft.au=Durmus%2C+Sinem&rft.au=Gelisgen%2C+Remise&rft.au=Uzun%2C+Hafize&rft.date=2024-09-05&rft.pub=MDPI+AG&rft.issn=2218-273X&rft.eissn=2218-273X&rft.volume=14&rft.issue=9&rft_id=info:doi/10.3390%2Fbiom14091123&rft.externalDocID=A810959470
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2218-273X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2218-273X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2218-273X&client=summon